Menu
Washingtoner
  • Home
  • Health
  • Artificial Intelligence
  • Technology
  • Entertainment
  • Real Estate
  • Software
  • Concealed Carry
  • Information Technology
Washingtoner

FreezeNit Announces Exclusive Licensing of Novel Non-Toxic Lice Treatment Technology
Washingtoner/10287890

Trending...
  • LS2 Partners with Angels Of Dirt's "Next Chapter Racer" Series Celebrating Women and Girls in Motorsports
  • Self-Published Dad's Santa Book Finally Found After 3 Years on Amazon
  • Citizens for West Virginia Election Integrity Urges "FOR" on Amendment 1
FreezeNit
Naturally-Derived OTC Gel Eliminates Lice Without Neurotoxins, Launching Spring 2025

MARBLEHEAD, Mass. - Washingtoner -- FreezeNit, a leader in innovative lice treatment solutions, is thrilled to announce the exclusive licensing of a novel over-the-counter (OTC) lice treatment gel designed to provide a safe, naturally-derived, and highly effective alternative to traditional synthetic or pesticide-based lice treatments.

Unlike conventional OTC lice treatments that rely on pesticide-based pyrethroids, which have decreasing efficacy due to lice resistance, this new technology works by a purely mechanical method of action to eliminate lice and their eggs. The patented formula is free from harsh chemicals and instead leverages natural abrasives, such as diatomaceous earth and walnut shell powder, orange oil extract, and conditioning agents to physically shred lice and nits, while being gentle on the hair and scalp.

This addition strengthens FreezeNit's growing product portfolio, reinforcing the company's mission to provide clean, effective, science-backed treatments that parents can trust.

"This is an incredibly exciting milestone for FreezeNit," said Joanna Shu, CEO of FreezeNit. "By securing exclusive rights to this novel technology, we're positioned to be on the cutting edge of first aid treatments that are gentle on kids. Traditional lice treatments have failed parents and kids, but with this gel, lice don't stand a chance."

More on Washingtoner
  • Commercial Manufacturing Validation Completed as November 10 FDA Milestone Approaches; Critical FDA Milestone Close: NRx Pharmaceuticals NAS DAQ: NRXP
  • Electives Launches "Electives for Everyone," Making Live Expert-Led Learning Available to Every Employee
  • Tax Tops the List as Wealthy Brits Plan Their Exit, La Vida Survey Finds
  • FloorLine Launches Live Shop Floor Tracking for Small Manufacturers
  • "The Tree of Cinema" Installation Brought Film History and Its Audiences Together at TIFF 2026

✔ Clinically Proven – was shown to be 96% effective in a clinical trial.
✔ No Resistance Issues – Unlike permethrin-based treatments, which have seen increased lice resistance, this technology works mechanically—not chemically—so lice cannot develop immunity.
✔ Patented & Protected – This novel formula and method of action is patented in the U.S., Canada, and the EU, ensuring exclusivity in the market.
✔ Class I, 510(k) Exempt – The FDA-regulated status allows for a fast-tracked market entry.

FreezeNit is actively engaging with retailers, distributors, and healthcare providers to bring this breakthrough lice treatment to families everywhere.

FreezeNit is an innovative healthcare company dedicated to revolutionizing first-aid with safe, effective, and science-backed solutions. By leveraging cutting-edge technology and natural alternatives to neurotoxins, FreezeNit provides families with fast, reliable, and pesticide-free treatments for head lice infestations.  For more information, visit www.FreezeNit.com.

Media Contact
Cathy Henry
cathy@freezenit.com
214-924-5992


Source: FreezeNit
Filed Under: Health

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on Washingtoner
  • Air Force Veteran Sean Douglas Delivers Powerful Suicide Prevention Presentations to Hundreds of Marines at Camp Pendleton
  • Breathwork Certification in Seattle, Washington State: First Pacific Northwest Date Set
  • Author Robert A. Robinson Introduces Anarchy at the AYP:
  • Renew Integrative Health Publishes Updated Peptide Therapy Guide to Help Patients Understand Their Options
  • AI Agents Are Getting Their Own Computers. HRTech Leading in Vertical Harness Development
  • UK Financial Ltd Announces Two-for-One Upgrade of Maya 3 to Maya 3G Token Using Chainlink Cross-Chain Technology
  • Critical FDA Milestone much Closer as Preservative-Free Ketamine Review Advances: NRx Pharmaceuticals (N A S D A Q: NRXP)
  • Spokane City Council Passes Community Safety Sales Tax
  • AutoProIT Achieves Cyber Essentials Certification, Reinforcing Its Commitment to Secure Digital Transformation
  • DayPass llega a ChatGPT y Claude
  • DayPass launches in ChatGPT and Claude
  • Renkeer Water Quality Sensors Support Efficient Operation of AI Liquid Cooling Systems
  • Victor Archibong Expands ItsArchiDuh Creator Brand
  • ClearSight Therapeutics Receives U.S. Patent Notice of Allowance
  • Revinate launches hospitality's first data activation platform
  • HLN Consulting Names Lilly Kan as Its First Chief Executive Officer
  • BitTitan Accelerates Large-Scale Document Migrations with MigrationWiz
  • Clearnetworx Deploys netElastic vBNG, CGNAT And netVision To Power Fiber Expansion Across Colorado's Western Slope
  • Spokane: SPD Seeks Assistance in Locating Vehicle Associated in Hit and Run
  • Tacoma: 'Capital Ready: Preparing Businesses for Growth in Public Contracting' Workshop on October 27
_catLbl0 _catLbl1

Popular on Washingtoner

  • Spokane: Police Arrest Registered Sex Offender for Child Sexual Abuse Material - 316
  • ResC4EU Final Event at KOMPOZYT-EXPO 2026 – Building Resilient European Supply Chains - 199
  • CinderLabs Launches AI Agent Marketplace: Nine Pre-Built Agents for Regulated Industries - 154
  • Spokane: Convicted Felon Arrested in Vancouver After Eluding SPD Officers - 144
  • City of Spokane to Install First 'Emergency Streets' Lane Closure After Weekend Fatal Crash - 144
  • City of Tacoma Invites Community Members to Share Their Experience Crossing I-5 - 130
  • Spokane: City and Permittable Partner to Support Rebuilding After Wildfires - 109
  • Inglewood Associates and Gordon Brothers Provide Update on Sale Process for 925 Euclid Avenue in Cleveland - 103
  • JEGS Launches Transformed Digital Commerce Platform Powered by PhaseZero
  • PropAccount.com Launches Marketing Hub Within PropGenie, Giving Prop Firm Operators an Automated Marketing Team

Similar on Washingtoner

  • Good Organics Now at Pop Up Grocer NYC With October 30 Sampling Event
  • KeysCaribbean Announces Temporarily Reduced Rates At Village at Hawks Cay Villas
  • Commercial Manufacturing Validation Completed as November 10 FDA Milestone Approaches; Critical FDA Milestone Close: NRx Pharmaceuticals NAS DAQ: NRXP
  • Detroit Lawyer Steals $600,000 Settlement Meant to Protect Child
  • Air Force Veteran Sean Douglas Delivers Powerful Suicide Prevention Presentations to Hundreds of Marines at Camp Pendleton
  • Breathwork Certification in Seattle, Washington State: First Pacific Northwest Date Set
  • Renew Integrative Health Publishes Updated Peptide Therapy Guide to Help Patients Understand Their Options
  • Critical FDA Milestone much Closer as Preservative-Free Ketamine Review Advances: NRx Pharmaceuticals (N A S D A Q: NRXP)
  • ClearSight Therapeutics Receives U.S. Patent Notice of Allowance
  • HLN Consulting Names Lilly Kan as Its First Chief Executive Officer
Copyright © 2026 washingtoner.com | Terms of Service | Privacy Policy | Contact Us | Contribute